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A study of women living with HIV (WLHIV) found that Mycoplasma genitalium (MG) is as 
common (~7% prevalence) as other cervical STIs and syndromic management would miss two-
thirds of infections. 
 
ABSTRACT  
We report the clinical symptoms and examination findings of Mycoplasma genitalium (MG) in 
women living with HIV (WLHIV) in South Africa. If we relied on syndromic management alone 
to treat MG, only 15/46 of MG-infected women would have received appropriate treatment: 
sensitivity 32.6% (95%CI: 19.5-48.0) and specificity 67.4% (95%CI: 63.4-71.2). 
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Mycoplasma genitalium (MG) is a sexually transmitted infection (STI) which may be associated 
with cervicitis, pelvic inflammatory disease (PID), preterm delivery, infertility, spontaneous 
abortion and HIV acquisition.(1) MG prevalence in the general population is estimated to be 1-
2%.(2, 3)  
 
Molecular diagnostic assays for MG are available and have regulatory approval in many 
countries including Europe, United States, the Middle East, Africa, Australia, New Zealand and 
parts of Asia. However, due to high costs of such detection methods (for MG as well as for 
chlamydia and gonorrhoea), few low- and middle-income countries are able to afford STI testing 
for these pathogens, and instead rely on syndromic management.(4) Though the syndromic 
approach is pragmatic when expensive diagnostics are not available, it has been criticized for its 
ineffectiveness in controlling STIs in multiple contexts.(5) Moreover, those infected with an STI 
but without symptoms or a clear syndrome would not receive treatment. 
 
To date, studies have suggested that HIV-negative women with MG may be more likely to have 
post-coital bleeding and abnormal vaginal discharge compared to women not infected with 
MG(2, 6), but detailed symptomatology of MG infection in WLHIV has not been extensively 
described. This study aims to determine the prevalence and clinical correlates of MG in WLHIV 













Cervical specimens used for MG detection were collected as part of an evaluation study of 
cervical cancer screening strategies in Burkina Faso and South Africa, as previously described 
(HARP - HPV in Africa Research Partnership).(7) Inclusion criteria were WLHIV, aged 25-50 
years, and residing in Ouagadougou or Johannesburg. This analysis focuses on WLHIV recruited 
in South Africa, as MG prevalence was found to be low in Burkina Faso (4/615, 0.6%). WLHIV 
were recruited from primary health care centres and surrounding communities in Johannesburg 
from December 2011 to October 2012. Data on self-reported clinical symptoms, suspected STI 
syndromes, socio-demographic and behavioural characteristics were collected by interviewer-
administered questionnaire. All participants were examined by trained study nurses and the 
following examination findings were recorded: vulval and/or vaginal inflammation, vaginal 
discharge and/or endocervical discharge, cervical contact bleeding, and pelvic pain on bimanual 
palpation. We also recorded information on the prescription of antibiotics according to the 
syndromic diagnosis made during the study visit which may be active against MG. 
 
Specimen collection and laboratory analysis 
For all women, a cervical swab was collected to detect Mycoplasma genitalium, Chlamydia 
trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis using a validated in-house real-
time multiplex polymerase chain reaction (mPCR) assay. Specimens that tested MG positive 
with the in-house mPCR assay were confirmed with the commercial Sacace MG real-time PCR 
assay (Sacace Biotechnologies, Como, Italy). All real-time PCR assays were performed using the 
Rotor-Gene platform (Qiagen, Hilden, Germany). We collected an ecto/endocervical swab using 







Digene cervical sampler (Qiagen, Courtaboeuf, France) for human papillomavirus (HPV) testing 
(Digene HC-II, Qiagen, Gaithersburg, Maryland USA) and genotyping (INNO-LiPA HPV 
genotyping Extra assay, Innogenetics, Courtaboeuf, France). A vaginal smear was Gram-stained 
for the diagnosis of bacterial vaginosis (BV, Nugent’s score of 7-10) and Candida spp. 
 
Venous blood was taken to perform herpes simplex virus type 2 (HSV-2) serology (Kalon IgG2 
ELISA, Kalon Diagnostics, Guilford, UK), Treponema pallidum haemagglutination assay 
(TPHA) and Immutrep® rapid plasma reagin (RPR) test (Omega Diagnostics,Scotland, UK), 
HIV-1 plasma viral load (Cobas Taqman, Roche Diagnostics,New Jersey, USA) and CD4+ T-
lymphocyte count (FACScount, Becton-Dickinson, Franklin Lakes, New Jersey, USA). 
 
Statistical analysis 
Multinomial multivariable logistic regression was used to compare women with no detectable 
pathogens (i.e. negative for MG and other STIs or reproductive tract infections (RTIs) such as 
BV and candidiasis) to women with: 1) MG positive, mono-infection; 2) MG positive, coinfected 
with other STI/RTI; and 3) MG negative but presence of other STI/RTI. We calculated adjusted 
odds ratios (AORs) alongside 95% confidence intervals (CI). Sensitivity was calculated as the 
probability of symptoms among those with MG, and specificity is the fraction of those without 
MG who do not have symptoms. Data were analyzed using STATA (StataCorp 2013) and we 












In total, 622 women with MG results (out of 623 women recruited) are included in this analysis 
(Supplementary Table 1). Their mean age was 35 years (+6.1), 43% had completed high school 
or above, and 82% reported having sex in the last three months. 
 
MG was detected in 7.4% (46/622, 95%CI: 5.5-9.7), Trichomonas vaginalis in 16.2%(95%CI: 
13.4-19.4), Chlamydia trachomatis in 5.0% (95%CI: 3.4-7.0), Neisseria gonorrhoeae in 
2.3%(95%CI: 1.2-3.7), BV in 41.6%(95%CI: 37.6-45.6), and Candida spp. in 8.5%(95%CI: 6.4-
11.0). MG was a mono-infection in 16 women (2.6%) and MG with STI/RTI coinfection in 30 
women (4.8%); whilst 343 women (55.1%) had no MG but another STI/RTI, and 233 women 
(37.5%) had no MG and no STI/RTI (uninfected). Symptoms were commonly reported by 
WLHIV: half of the women (52%, 343/623) reported at least one of the following symptoms: 
dysuria, genital itch, lower abdominal pain, vaginal discharge, dyspareunia, or post-coital 
bleeding.  
 
Among women with MG, half were symptomatic (54%, 25/46). The most common STI/RTI 
coinfections were: BV (47.8%, 22/46), T. vaginalis (15.2%, 7/46), candidiasis (10.9%, 5/46), and 
C. trachomatis (4.4%, 2/46). In the 16 women with MG mono-infection, the majority were 
asymptomatic (75%, 12/16).  
 
Table 1 presents the value of clinical symptoms or examination findings to diagnose MG. We 
assessed for differences between women who have no STI/RTI (uninfected) compared with 
women with: 1) MG mono-infection; 2) MG co-infected with another STI/RTI; and 3) no MG 







but have another STI/RTI.  We found that it was not possible to distinguish these groups from 
one another by just using clinical history or examination findings.  
 
If we relied on syndromic management alone (i.e. clinician-suspected PID, vaginal discharge 
syndrome or any STI syndrome) to treat MG, only 15/46 of MG-infected women would have 
received any antibiotics: sensitivity 32.6% (95%CI: 19.5-48.0) and specificity 67.4% (95%CI: 
63.4-71.2). One woman received azithromycin and doxycycline, and 14 women received 
doxycycline alone.  
 
DISCUSSION 
To our knowledge, this is the first study to comprehensively evaluate the clinical profile of MG 
in WLHIV in a LMIC. We extend the literature by showing MG was as common as other STIs 
but challenging to diagnose without using molecular diagnostics. The current practice of 
syndromic STI management will miss two-thirds of MG cases in this population of WLHIV, 
consistent with another South African study among WLHIV showing that syndromic 
management would miss 11/16 (69%) MG.(8) This is higher than missed chlamydia (44%), 
gonorrhoea (40%) and trichomoniasis (33%) using syndromic management.(8)  
 
The main strength of the study is that we evaluated a large number of WLHIV who had 
comprehensive assessments of genital symptoms, clinical examination and all were tested for 
mucosal STI/RTIs. This allowed us to carefully assess the clinical features of MG compared with 
women with no infection and other STI/RTIs. A limitation with this approach was that the 
recorded symptoms and clinical findings were dependent on the skills of the trained research 







nurses but this reflects the real-world level of care provided by nurses in South Africa. Our MG 
prevalence may be an underestimate as we tested cervical swabs (rather than vaginal swabs) and 
for the purpose of this study, we confirmed all MG positive cases on mPCR with a second MG 
test (MG Sacace).(9) 
 
The reliance on patient-reported symptoms and clinical signs to identify women with MG would 
be challenging without molecular diagnostics. MG, by itself, is associated with relatively low 
inflammation compared to other STIs,(3) and so are often asymptomatic. Our findings that 46% 
of women with MG were asymptomatic is similar to a UK-based study that reported 56% of 
HIV-negative women with MG were asymptomatic.(2) When we excluded women with other 
STIs/RTIs, we found that 75% of women with MG mono-infection were asymptomatic. Though 
studies in HIV-negative women reported higher likelihood of post-coital bleeding and abnormal 
vaginal discharge for women with MG,(2, 6) our study among WLHIV demonstrates the 
difficulties of identifying MG in a real-world setting. The specificity of symptoms or signs for 
MG was low in a population where half of the women reported at least one urogenital symptom, 
and a high proportion were diagnosed with bacterial vaginosis (42%).  
 
Our study findings have direct policy implications. First, the syndromic approach would not be 
sensitive or specific enough to detect MG in WLHIV. Second, in settings where MG is frequent 
but no testing is available, the choice of antibiotics included in syndromic STI management 
should, if possible, treat MG and reflect the local resistance profile of MG to ensure that MG is 
covered appropriately, and prevent the development of further resistance. Effective management 
of MG ideally require diagnostics with AMR detection that can also guide therapy.(10)  







In conclusion, MG infection is as common as other cervical STIs among WLHIV in South Africa 
but is challenging to diagnose based on clinical symptoms and examination findings alone. 
Molecular diagnostics with AMR testing for MG and Neisseria gonorrhoeae are needed for 
accurate detection so that appropriate treatment can be offered. In the absence of MG diagnostics, 
the drugs used in syndromic management of STIs should be carefully selected to cover for MG 
without fostering the development of resistance. MG-AMR monitoring should be included in 
future STI-AMR monitoring along that of Neisseria gonorrhoeae.  
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Table 1. Multinomial multivariable logistic regression to compare among 622 WLHIV in South Africa, those with no MG and no STI/RTI (uninfected, 
i.e. MG- STI/RTI-, n=233) with WLHIV who had 1) MG mono-infection (MG+ STI/RTI-, n=16), 2) MG coinfection with another STI/RTI (MG+ 
STI/RTI+, n=30), and 3) no MG with another STI/RTI (MG- STI/RTI+, n=343)  
Characteristic MG+ STI/RTI-  
vs. uninfected  
APOR# (95% CI) 
P value MG+ STI/RTI+  
vs. uninfected 
APOR# (95% CI) 
P value MG- STI/RTI+  
vs. uninfected  
APOR# (95% CI) 
P value 
Self-reported symptoms       
Dysuria (n=80) 0.33 (0.04-3.01) 0.325 3.23 (1.30-8.05)* 0.012 1.12 (0.66-1.90) 0.663 
Genital itch (n=110) 0.83 (0.20-3.42) 0.796 1.93 (0.79-4.68) 0.146 1.16 (0.73-1.84) 0.536 
Lower abdominal pain (n=158) 0.23 (0.04-1.37) 0.106 1.70 (0.75-3.86) 0.206 1.02 (0.69-1.52) 0.911 
Vaginal discharge (n=82) Ø - 3.77 (1.43-9.92)** 0.007 2.07 (1.18-3.62)* 0.011 
Dyspareunia (n=112) 0.34 (0.04-2.73) 0.312 1.55 (0.60-3.96) 0.364 1.32 (0.84-2.07) 0.223 
Post coital bleeding (n=35) 0.92 (0.10-8.33) 0.940 1.03 (0.21-5.00) 0.973 0.81 (0.39-1.69) 0.573 
Clinical signs       
Vulval inflammation (n=4) Ø - 7.37 (0.41-133.80) 0.177 1.23 (0.11-13.70) 0.869 
Vaginal inflammation (n=8) Ø - 4.55 (0.26-78.35) 0.296 3.44 (0.41-28.98) 0.255 
Vaginal discharge (n=165) 0.41 (0.09-1.94) 0.261 1.14 (0.47-2.77) 0.780 1.58 (1.06-2.34)* 0.023 
Endocervical discharge (n=74) 0.40 (0.05-3.32) 0.399 0.47 (0.10-2.11) 0.321 0.95 (0.57-1.60) 0.849 
Contact bleeding (n=267) 0.79 (0.26-2.42) 0.682 0.82 (0.36-1.86) 0.633 1.44 (1.02-2.03)* 0.038 
Clinician diagnosis       
Any STI syndrome (n=192) 1.03 (0.77-1.36) 0.861 1.03 (0.81-1.31) 0.797 1.05 (0.86-.1.28) 0.636 
Vaginal discharge syndrome (n=98) 0.45 (0.06-3.58) 0.449 2.29 (0.91-5.79) 0.079 1.49 (0.92-2.42) 0.109 
Pelvic inflammatory disease (PID) syndrome (n=9) Ø - Ø - 3.00 (0.74-12.18) 0.123 







Ø too few cases to estimate model;  # adjusted for age, HIV-1 plasma viral load >1000 copies/mL and syphilis; * p<0.05, ** p<0.01,  
*** p<0.001; APOR = adjusted prevalence odds ratio, MG = Mycoplasma genitalium, RTI = reproductive tract infections (i.e. bacterial vaginosis, candidiasis), 
PID = pelvic inflammatory disease, STI = sexually transmitted infection (i.e. N. gonorrhoeae, C. trachomatis, T. vaginalis), 95% CI = 95% confidence interval 
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